收藏切换
Risk assessment of tumorigenicity and oncogenicity of cell therapy products
收藏切换
Zhe QU, Zhi LIN, Gui-tao HUO, Tian-tian HOU, Yan-wei YANG, Di ZHANG, Xing-chao GENG, Bo LI, Yan HUO
Chinese Journal of New Drugs | 2021, 30(19) : 1819 - 1824
Less
收藏切换
Chinese Journal of New Drugs | 2021, 30(19): 1819-1824
Risk assessment of tumorigenicity and oncogenicity of cell therapy products
Full
Zhe QU, Zhi LIN, Gui-tao HUO, Tian-tian HOU, Yan-wei YANG, Di ZHANG, Xing-chao GENG, Bo LI, Yan HUO
Affiliations
  • Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China
Published: 2021-10-15
Outline
收藏切换

Cell therapy products (CTPs) have the potential of tumor formation risks, i.e., tumorigenicity, oncogenicity and tumor-enhancement. Since the final stem cell therapy products derived from human embryonic stem cells and human induced pluripotent stem cells may contain undifferentiated hPSCs, malignant transformed cells/mutations and genetic instability, they have the highest risk of tumorigenicity. Tumorigenicity and oncogenicity risk of CTPs may be largely increased in genetically modified stem cells, that express foreign genes (such as various growth factors), as well as the oncogene activated by insertion mutations of genetically modified viral vectors (such as retroviruses and lentiviruses). While terminally differentiated somatic cell products have lower risk of tumorigenicity. During recent years, increasing number of cell therapy products have entered the clinical application, the tumor formation risk of which is a safety issue that is concerned by product developers and regulatory authorities. This article introduces the concepts of tumorigenicity, oncogenicity and tumor-enhancement of CTPs, providing a comprehensive overview of the current evaluation methods in vitro and in vivo, as well as the general considerations for risk assessment of tumorigenicity and oncogenicity of CTPs.

cell therapy products  /  tumorigenicity  /  oncogenicity  /  tumor-enhancement  /  risk assessment
屈哲, 林志, 霍桂桃, 侯田田, 杨艳伟, 张頔, 耿兴超, 李波, 霍艳. 细胞治疗产品的成瘤性和致瘤性风险评价. 中国新药杂志, 2021 , 30 (19) : 1819 -1824 .
Zhe QU, Zhi LIN, Gui-tao HUO, Tian-tian HOU, Yan-wei YANG, Di ZHANG, Xing-chao GENG, Bo LI, Yan HUO. Risk assessment of tumorigenicity and oncogenicity of cell therapy products[J]. Chinese Journal of New Drugs, 2021 , 30 (19) : 1819 -1824 .
Year 2021 volume 30 Issue 19
23
2
Cite this Article
BibTeX
Article Info
  • Online Date:2026-10-30
  • Published:2021-10-15
Article Data
Affiliations
History
  • Accepted:2021-05-21
Funding
Affiliations
    Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT